New cancer drug OP-3136 enters first human tests

NCT ID NCT06784193

Recruiting now Disease control Sponsor: Olema Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called OP-3136 in people with advanced breast, lung, or prostate cancers that have not responded to other treatments. The drug works by blocking certain enzymes that help cancer cells grow. The study will first find a safe dose, then test it alone or with other drugs. About 180 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OP-3136 (a KAT6A/B inhibitor drug)
What this could lead to: If successful, this could point toward a new treatment option for advanced breast, lung, or prostate cancers that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial, so the drug may not be safe or effective. Only a small number of participants will receive it, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm castration-resistant prostate carcinoma estrogen-receptor positive breast cancer hormone receptor-positive breast cancer non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ADVANCED OR METASTATIC ER+ HER2- BREAST CANCER (MBC) ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) FULVESTRANT METASTATIC BREAST CANCER PALAZESTRANT

Contacts and locations

Locations

Cancer Research South Australia
RECRUITING

Adelaide, South Australia, 5000, Australia
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
START - Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
START - Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States
START - San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
University Medical Center - New Orleans
RECRUITING

New Orleans, Louisiana, 70112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.